AU2012304909B2 - Sustained release formulations for delivery of proteins to the eye and methods of preparing same - Google Patents

Sustained release formulations for delivery of proteins to the eye and methods of preparing same Download PDF

Info

Publication number
AU2012304909B2
AU2012304909B2 AU2012304909A AU2012304909A AU2012304909B2 AU 2012304909 B2 AU2012304909 B2 AU 2012304909B2 AU 2012304909 A AU2012304909 A AU 2012304909A AU 2012304909 A AU2012304909 A AU 2012304909A AU 2012304909 B2 AU2012304909 B2 AU 2012304909B2
Authority
AU
Australia
Prior art keywords
formulation
atec
plga
tocopherol
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012304909A
Other languages
English (en)
Other versions
AU2012304909A1 (en
Inventor
Glenn T. Huang
Vernon G. Wong
Louis L. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramscor Inc
Icon Bioscience Inc
Original Assignee
Ramscor Inc
Icon Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramscor Inc, Icon Bioscience Inc filed Critical Ramscor Inc
Publication of AU2012304909A1 publication Critical patent/AU2012304909A1/en
Assigned to RAMSCOR, INC., ICON BIOSCIENCE, INC. reassignment RAMSCOR, INC. Amend patent request/document other than specification (104) Assignors: VERNON G WONG
Application granted granted Critical
Publication of AU2012304909B2 publication Critical patent/AU2012304909B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012304909A 2011-06-10 2012-06-11 Sustained release formulations for delivery of proteins to the eye and methods of preparing same Active AU2012304909B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161495672P 2011-06-10 2011-06-10
US61/495,672 2011-06-10
PCT/US2012/041950 WO2013036309A2 (en) 2011-06-10 2012-06-11 Sustained release formulations for delivery of proteins to the eye and methods of preparing same

Publications (2)

Publication Number Publication Date
AU2012304909A1 AU2012304909A1 (en) 2013-12-19
AU2012304909B2 true AU2012304909B2 (en) 2017-06-08

Family

ID=47832748

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012304909A Active AU2012304909B2 (en) 2011-06-10 2012-06-11 Sustained release formulations for delivery of proteins to the eye and methods of preparing same

Country Status (21)

Country Link
US (1) US9814773B2 (es)
EP (1) EP2717914B1 (es)
JP (1) JP6339011B2 (es)
KR (1) KR20140060274A (es)
CN (1) CN103945865B (es)
AU (1) AU2012304909B2 (es)
BR (1) BR112013031685B1 (es)
CA (1) CA2838289C (es)
CY (1) CY1122771T1 (es)
DK (1) DK2717914T3 (es)
ES (1) ES2761340T3 (es)
HR (1) HRP20192276T1 (es)
HU (1) HUE047737T2 (es)
IN (1) IN2013MN02384A (es)
LT (1) LT2717914T (es)
MX (1) MX359119B (es)
PL (1) PL2717914T3 (es)
PT (1) PT2717914T (es)
RS (1) RS60051B1 (es)
SI (1) SI2717914T1 (es)
WO (1) WO2013036309A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913336C (en) * 2013-05-24 2020-12-15 Icon Bioscience, Inc. Use of sustained release dexamethasone in post-cataract surgery inflammation
SG11201608835VA (en) * 2014-05-08 2016-11-29 Panoptes Pharma Ges M B H Compounds for treating ophthalmic diseases and disorders
EP3272362B1 (en) * 2015-03-18 2023-12-13 Santen Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
CA2991015A1 (en) * 2015-07-01 2017-01-05 Santen Pharmaceutical Co., Ltd. Depot preparation containing citric acid ester
EA036951B1 (ru) * 2015-08-03 2021-01-19 Толмар Интернэшнл Лимитед Жидкая полимерная система доставки для длительного введения лекарственных средств
HUE063850T2 (hu) 2015-09-21 2024-02-28 Teva Pharmaceuticals Int Gmbh Hosszan tartó felszabadulású olanzapin készítmények
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
KR101957599B1 (ko) 2017-10-23 2019-03-13 김상현 훈제 단무지 제조 방법, 이에 의해 제조된 훈제 단무지
EP3749386A4 (en) 2018-02-09 2021-10-27 Icon Bioscience, Inc. SYSTEMS, KITS AND METHODS FOR LOADING AND DISPENSING A SMALL VOLUME DOSE FROM A SYRINGE
JP2021523223A (ja) 2018-05-01 2021-09-02 チビ，インコーポレイティド 眼への薬物の非侵襲的な持続型送達のための液体デポー
AU2019262061A1 (en) 2018-05-01 2020-11-26 Chibi, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
EP4153214A4 (en) * 2020-05-22 2024-06-26 Trustees of Boston University METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASE
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
KR20240117521A (ko) 2021-07-06 2024-08-01 마크 하슬레톤 세로토닌 재흡수 억제제 금단 증후군의 치료

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658432B1 (fr) * 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
NZ523385A (en) * 2000-06-28 2005-09-30 Atul J Biodegradable vehicles and BAS-loaded delivery systems for use as biodegradable fillers and/or spacers, e.g. artificial skin
AR039729A1 (es) * 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
US20050079202A1 (en) * 2003-05-30 2005-04-14 Guohua Chen Implantable elastomeric depot compositions and uses thereof
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
MX366832B (es) * 2004-10-01 2019-07-24 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
AU2005294382A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CA2792484C (en) * 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
ES2672806T3 (es) * 2009-07-03 2018-06-18 Armbruster Biotechnology Gmbh Injerto óseo y material biocompuesto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANAND, O., published December 2008, pages 1-119 (Online Dissertation), [retrieved from internet on 6 June 2016] <URL: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.692.2608&rep=rep1&type=pdf *
KUNO, N. et al., ‘Recent Advances in Ocular Drug Delivery Systems’, Polymers. 6 January 2011, Vol. 3, No. 1, pages 193-221 *

Also Published As

Publication number Publication date
WO2013036309A3 (en) 2013-05-10
KR20140060274A (ko) 2014-05-19
US20140140992A1 (en) 2014-05-22
EP2717914A4 (en) 2015-05-13
CA2838289A1 (en) 2013-03-14
AU2012304909A1 (en) 2013-12-19
MX2013014461A (es) 2014-05-14
NZ619707A (en) 2015-01-30
BR112013031685B1 (pt) 2021-04-06
US9814773B2 (en) 2017-11-14
JP6339011B2 (ja) 2018-06-06
BR112013031685A2 (pt) 2017-02-07
IN2013MN02384A (es) 2015-06-12
EP2717914B1 (en) 2019-10-30
PL2717914T3 (pl) 2020-05-18
MX359119B (es) 2018-09-14
LT2717914T (lt) 2020-03-25
JP2014516087A (ja) 2014-07-07
WO2013036309A2 (en) 2013-03-14
HUE047737T2 (hu) 2020-05-28
CY1122771T1 (el) 2021-05-05
ES2761340T3 (es) 2020-05-19
HRP20192276T1 (hr) 2020-05-15
DK2717914T3 (da) 2020-01-20
CA2838289C (en) 2019-09-10
EP2717914A2 (en) 2014-04-16
SI2717914T1 (sl) 2020-07-31
RS60051B1 (sr) 2020-04-30
CN103945865B (zh) 2016-10-26
PT2717914T (pt) 2019-12-18
CN103945865A (zh) 2014-07-23

Similar Documents

Publication Publication Date Title
AU2012304909B2 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
Kang-Mieler et al. Advances in ocular drug delivery systems
Giri et al. Prospects of pharmaceuticals and biopharmaceuticals loaded microparticles prepared by double emulsion technique for controlled delivery
JP5682991B2 (ja) 便利に移植可能な徐放性薬物処方物
US8318169B2 (en) Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier
JP2007535536A (ja) 高分子含有持続放出眼内インプラントおよび関連方法
US8877229B2 (en) Controlled release microparticles
CN111481513B (zh) 缓释微球药物递送系统及其制备方法
EP3621588B1 (en) Ocular compositions
Rahmani et al. The recent advancement in the PLGA-based thermo-sensitive hydrogel for smart drug delivery
Boddu et al. Novel nanoparticulate gel formulations of steroids for the treatment of macular edema
Ugurlu et al. Transscleral delivery of bevacizumab-loaded chitosan nanoparticles
WO2020243608A1 (en) Bioerodible polyester polymer implants and related methods of use
NZ619707B2 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
Marques et al. PKPD of PLGA-PEG-PLGA Copolymeric Micelles
US20220054407A1 (en) Ocular compositions
WO2024206077A2 (en) Dosing regimes and combination therapies using archexin for the treatment of cancer
Kimura et al. Biodegradable systems
TW201238609A (en) Conveniently implantable sustained release drug compositions

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ WONG, VERNON G.; WOOD, LOUIS L. AND HUANG, GLENN T.

FGA Letters patent sealed or granted (standard patent)